GlaxoSmithKline (GSK) Rating Lowered to Sell at ValuEngine

GlaxoSmithKline (NYSE:GSK) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Friday.

Several other brokerages also recently weighed in on GSK. Zacks Investment Research downgraded shares of GlaxoSmithKline from a “buy” rating to a “hold” rating and set a $46.00 target price on the stock. in a research note on Wednesday, April 11th. Deutsche Bank reissued a “neutral” rating on shares of GlaxoSmithKline in a research note on Monday, April 9th. BNP Paribas raised shares of GlaxoSmithKline from a “neutral” rating to an “outperform” rating in a research note on Wednesday, April 4th. JPMorgan Chase reissued a “neutral” rating on shares of GlaxoSmithKline in a research note on Monday, January 29th. Finally, Barclays raised shares of GlaxoSmithKline from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 16th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $40.21.

Get GlaxoSmithKline alerts:

Shares of GSK opened at $39.82 on Friday. GlaxoSmithKline has a twelve month low of $34.52 and a twelve month high of $44.53. The firm has a market capitalization of $98,185.59, a PE ratio of 13.83, a PEG ratio of 2.04 and a beta of 0.82. The company has a current ratio of 0.61, a quick ratio of 0.40 and a debt-to-equity ratio of 3.90.

GlaxoSmithKline (NYSE:GSK) last announced its earnings results on Wednesday, April 25th. The pharmaceutical company reported $0.68 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.70 by ($0.02). GlaxoSmithKline had a net margin of 3.50% and a return on equity of 144.84%. The firm had revenue of $10.04 billion during the quarter, compared to analysts’ expectations of $10.26 billion. equities research analysts predict that GlaxoSmithKline will post 2.95 earnings per share for the current year.

A number of hedge funds have recently bought and sold shares of the stock. Keystone Financial Planning Inc. increased its stake in GlaxoSmithKline by 1.1% in the 1st quarter. Keystone Financial Planning Inc. now owns 130,520 shares of the pharmaceutical company’s stock worth $5,099,000 after buying an additional 1,418 shares during the period. FTB Advisors Inc. increased its stake in GlaxoSmithKline by 38.6% in the 1st quarter. FTB Advisors Inc. now owns 5,180 shares of the pharmaceutical company’s stock worth $209,000 after buying an additional 1,443 shares during the period. Profund Advisors LLC increased its stake in GlaxoSmithKline by 3.0% in the 4th quarter. Profund Advisors LLC now owns 52,264 shares of the pharmaceutical company’s stock worth $1,854,000 after buying an additional 1,519 shares during the period. Atria Investments LLC increased its stake in GlaxoSmithKline by 17.1% in the 4th quarter. Atria Investments LLC now owns 12,830 shares of the pharmaceutical company’s stock worth $455,000 after buying an additional 1,874 shares during the period. Finally, Whittier Trust Co. increased its stake in GlaxoSmithKline by 71.0% in the 1st quarter. Whittier Trust Co. now owns 4,520 shares of the pharmaceutical company’s stock worth $177,000 after buying an additional 1,876 shares during the period. 11.04% of the stock is currently owned by institutional investors.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Leave a Reply

Your email address will not be published. Required fields are marked *